Drug therapy for infants with cardiac disease

Newborn and Infant Nursing Reviews

Volumn 2, Issue 2, 2002, Pages 60-74

  Strodtbeck, Frances ^a,b   Theorell, Catherine ^a  

^a BAYLOR UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; AMRINONE; ANTIARRHYTHMIC AGENT; BRETYLIUM; CAPTOPRIL; CARDIOVASCULAR AGENT; DIGOXIN; DOBUTAMINE; DOPAMINE; ENALAPRIL; ESMOLOL; FLECAINIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; ISOPRENALINE; LIDOCAINE; MILRINONE; NITROPRUSSIDE SODIUM; NORADRENALIN; PHENYTOIN; PHOSPHODIESTERASE INHIBITOR; PROCAINAMIDE; PROPRANOLOL; SOTALOL; TOCAINIDE; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

ARTICLE; CHILD CARE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG INDICATION; HEART ARRHYTHMIA; HEART DISEASE; HEART INNERVATION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; INFANT; LUNG EDEMA; LUPUS ERYTHEMATOSUS; NEWBORN; NEWBORN INTENSIVE CARE; PHARMACODYNAMICS; PROGNOSIS; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 0036296074     PISSN: 15273369     EISSN: None     Source Type: Journal    
DOI: 10.1053/nbin.2002.33060     Document Type: Article

References (104)

1. Pharmacokinetics of cardiovascular drugs in children. Inotropes and vasopressors
2. Pharmacology of the cardiovascular system
3. Cardiovascular pharmacology
4. Developmental pharmacology of adrenergic agents
5. Cardiac drugs
6. Pharmacology of cardiovascular drugs
7. Catecholamines, inotropic medications, and vasopressor agents
8. Neonatal cardiovascular pharmacology
9. Cardiovascular drugs
10. In utero management of hydrops fetalis caused by critical aortic stenosis
11. Digoxin. The drug of choice for the in-utero treatment of paroxysmal supraventricular tachycardia
12. Pharmacologic therapy
13. Neonatal cardiovascular pharmacology
14. A blind, randomized comparison of the circulatory effects of dopamine and epinephrine infusions in the newborn piglet during normoxia and hypoxia
15. Treatment of peripheral tissue ischemia with topical nitroglycerin ointment in neonates
16. Phentolamine use in a neonate for the prevention of dermal necrosis caused by dopamine: A case report
17. Alterations in dopamine clearance and catechol-O-methyltransferase activity by dopamine infusions in children
18. Dopamine clearance in critically ill infants and children: Effect of age and organ system dysfunction
19. Dopamine versus dobutamine for hypotensive preterm infants
20. Randomized, blind trial of dopamine versus dobutamine for treatment of hypotension in preterm infants with respiratory distress syndrome
21. Randomized trial comparing dopamine and dobutamine in preterm infants
22. Controversies in the diagnosis and management of hypotension in the newborn infant
23. Circulatory support of the sick preterm infant
24. Impact on blood pressure and intestinal perfusion of dobutamine or dopamine in hypotensive preterm infants
25. Assessment of therapy for arterial hypotension in critically ill preterm infants
26. Supranormal cardiac output in the dopamine- and dobutamine-dependent preterm infant
27. Comparison of the hemodynamic effects of dopamine and dobutamine in young children undergoing cardiac surgery
28. The need for inotropic support in a subgroup of infants with severe life-threatening respiratory syncytial viral infection
29. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure
30. Effects of dopamine on liver blood flow in children with congenital heart disease
31. Effects of dopamine and dobutamine on regional blood flow distribution in the neonatal piglet
32. Role of corticosteroids in neonatal blood pressure homeostasis
33. Cardiovascular effects of hydrocortisone in preterm infants with pressor-resistant hypotension
34. The hemodynamic effects of dopamine and volume expansion in sick preterm infants
35. Regional hemodynamic effects of dopamine in the sick preterm neonate
36. Pulse oximetry in newborn infants with birth weights of 620 to 4285 grams receiving dopamine and dobutamine
37. Effects of low-dose dobutamine on left ventricular diastolic filling in children
38. Amrinone in neonates and children after cardiac surgery
39. The acute pharmacokinetics and pharmacodynamics of amrinone in pediatric patients
40. A comparison of the hemodynamic effects of amrinone and sodium nitroprusside in infants after cardiac surgery
41. Amrinone versus dopamine-nitroglycerin after reconstructive surgery for complete atrioventricular septal defect
42. Amrinone versus dopamine and nitroglycerin in neonates after arterial switch operation for transposition of the great arteries
43. Amrinone improves lung compliance in patients receiving mechanical ventilation for cardiogenic pulmonary edema
44. Hemodynamic effects of N-acetylamrinone in a porcine model of group B streptococcal sepsis
45. Pharmacologic therapy of persistent pulmonary hypertension of the newborn
46. The use of L-arginine [correction of F-arginine] and phosphodiesterase inhibitors (dipyridamole) to wean from inhaled nitric oxide
47. Effects of single administration of a phosphodiesterase III inhibitor during cardiopulmonary bypass: Comparison of milrinone and amrinone
48. Amrinone increases ventricular contractility and diastolic compliance in endotoxemia
49. Selective pulmonary and systemic vasodilator effects of amrinone in children: New therapeutic implications
50. Amrinone versus dobutamine in cardiac surgical patients with severe pulmonary hypertension after cardiopulmonary bypass: A prospective, randomized double-blinded trial
51. Endothelium-dependent relaxation of rat thoracic aorta by amrinone-induced nitric oxide release
52. The pharmacokinetics of captopril in infants with congestive heart failure
53. Efficacy and dosage of enalapril in congenital and acquired heart disease
54. Treatment of heart failure in infants and children
55. Pharmacologic considerations in the neonate with congenital heart disease
56. Pharmacological approach to the management of neonatal hypertension
57. Quinidine and unidirectional ion fluxes in atria
58. Effect of procainimide, quinidine and ajmaline in the Wolff-Parkinson-White syndrome
59. The influence of quinidine on serum digoxin concentrations
60. Polymorphic acetylation of procainimde in healthy subjects
61. Procainamide elimination kinetics in pediatric patients
62. Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide
63. Antiarrhythmic drugs
64. Newer antiarrhythmic agents in children
65. On the metabolism of lidocaine. II. The biotransformation of lidocaine
66. Control of late postoperative ventricular arrhythmias with phenytoin in young patients
67. Phenytoin therapy for ventricular arrhythmias occurring late after surgery for congenital heart disease
68. Verapamil therapy for stable exertional angina pectoris
69. Mexiletine: An effective antiarrhythmic drug for treatment of ventricular arrhythmias in congenital heart disease
70. Tocainide
71. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide
72. Flecainide acetate for treatment of tachyarrhythmias in children: Review of world literature on efficacy, safety, and dosing
73. Unusual electrocardiogram findings in a preterm infant after fetal tachycardia with hydrops fetalis treated with flecainide
74. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias
75. Usefulness of intravenous propafenone for control of postoperative junctional ectopic tachycardia
76. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study)
77. Effectiveness of low dose captropril versus propranolol therapy in infants with severe congestive failure due to left-to-right shunts
78. Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PRO-INFANT Trial. Congestive heart failure in infants treated with propranolol
79. Supraventricular tachycardia in children: Clinical features, response to treatment, and long-term follow-up in 217 patients
80. Vitros digoxin immunoassay evaluated for interference by digoxin-like immunoreactive factors
81. Oral propranolol treatment in infants and children
82. Cardiovascular and antiarrhythmic effects of esmolol in children
83. Pharmacodynamics and pharmacokinetics of esmolol: A short-acting beta-blocking agent in children
84. Pharmacokinetics of esmolol in children
85. Amiodarone: Electrophysiologic actions, pharmacokinetics and clinical effects
86. Safety and efficacy of short and long-term verapamil therapy in children with tachycardia
87. Amiodarone used alone and in combination with propranolol: A very effective therapy for tachyarrhythmias in infants and children
88. Acute pulmonary toxicity in an infant from intravenous amiodarone
89. Amiodarone induced pulmonary fibrosis in infancy
90. Safety issues in the treatment of pediatric supraventricular tachycardias
91. Fetal supraventricular tachycardia treated with sotalol
92. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: Particular reference to sotalol
93. Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia
94. Verapamil therapy in infants with hypertrophic cardiomyopathy
95. Serum concentrations and serum half-life of digoxin in premature and mature newborns
96. Rapid and safe termination of supraventricular tachycardia in children by adenosine
97. Use of adenosine for diagnosis and treatment of tachyarrhyhtmias in pediatric patients
98. Efficacy and safety in the treatment of supraventricular tachycardia in infants and children
99. Adenosine and pediatric supraventricular tachycardia in the emergency department: Multicenter study and review
100. Adenosine in the management of supraventricular tachycardia in children
101. Fetal and neonatal arrhythmias
102. Usefulness of adenosine for arrhythmias in infants and children
103. Adenosine in altering short- and long-term treatment of supraventricular tachycardia in infants